ArticleFrontiers in pediatrics2026
Reduced NLRP3, AIM2 and NLRC4 inflammasome activity in cord blood of extremely preterm infants.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pro-inflammatory caspase-1 is a key player in innate immunity. Physiological activation of the inflammasome/caspase-1 pathway supports host defense against pathogens, whereas dysregulated activation contributes to the pathogenesis of neonatal diseases such as bronchopulmonary dysplasia. Although preterm infants exhibit reduced IL-1β secretion from monocytes compared with term infants, a comprehensive functional characterization of distinct inflammasome pathways is lacking. Objective: To specifically analyze the activity of NLRP3, AIM2 and NLRC4 inflammasomes in cord blood of pre- and full-term infants and in peripheral blood of healthy adults. Methods: A validated whole-blood assay was used to specifically activate the different inflammasomes. IL-1β was analyzed as a surrogate marker of inflammasome/caspase-1 activation. RT-qPCR was used to measure expression of inflammasome related genes in leukocytes. Results: Activity of the NLRP3 and AIM2 inflammasomes was reduced in cord blood of preterm infants, particularly those born at <28 weeks of gestation, compared with term infants and adults. NLRC4 inflammasome activity was significantly reduced only in preterm infants with gestational age <32 weeks. No significant differences were observed between full-term infants and adult controls. Gene expression analysis revealed an age-dependent upregulation of NLRP3, AIM2, NLRC4, ASC, CASP1 and IL1B, with expression levels increasing from preterm to term gestation and even further towards adulthood. Conclusion: Activity of the inflammasome/caspase-1 pathway correlates with gestational age and is significantly reduced in preterm infants compared with full-term infants or adults. This finding contrasts with the high incidence of preterm-specific disorders where dysregulated caspase-1 activation is implicated in disease pathogenesis. Future research should investigate the dynamic evolution of inflammasome activity during the first days of life to elucidate its role in the onset of neonatal diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.